

CSD/NSE&BSE/2020-21
June 24, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Large Corporate – Initial Confirmation

.....

With reference to above subject, we enclosed herewith confirmation for the financial year ended 31 March, 2020 in the prescribed format, under the SEBI Circular SEBI/HO/DDHS/CIR/P/2018/ 144 dated November 26, 2018.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

Regd. Office : 8-2-334, SDE Serene Chambers, 3rd Floor, Road No.5, Avenue 7,
Banjara Hills, Hyderabad - 500 034. Telangana, India. CIN : L24299TG2018PLC128171
Tel: 91 40 2354 9414, Fax : 91 40 2354 1152, Email: info@suvenpharm.com, Website: www.suvenpharm.com

CONFIRMATION

<i>Sr. No.</i>	<i>Particulars</i>	<i>Details</i>
1.	Name of the company	SUVEN PHARMACEUTICALS LIMITED
2.	CIN	L24299TG2018PLC128171
3.	Outstanding borrowing of company as on 31st March 2020, (in Rs Cr)	₹ 91.25 Crores
4.	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	Not applicable
5.	Name of Stock Exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	Not applicable

We confirm that the outstanding long-term borrowing of the Company as on 31st March, 2020 is less than Rs. 100 crores accordingly, the Company is not a 'Large Corporate' for the purpose of the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.



K. Hanumantha Rao
 Company Secretary



P. Subba Rao
 Chief Financial Officer

Date: June 24, 2020

Suven Pharmaceuticals Limited